CA
NZ
UK
AU
IND
US
U.S.-Iran tensions have sent crude oil prices sharply higher, with Brent briefly crossing $80 per barrel, a tailwind for midstream infrastructure demand. Multiple institutional investors have been building positions in Energy Transfer, and analysts maintain a consensus Buy rating with a $23.45 average price …
Shares are sharply underperforming the broader market, as renewed U.S.-Iran hostilities rattled global sentiment and pressured small-cap media and ad-tech names. The selloff comes despite Entravision's strong Q1 2026 print in May, when shares surged 74% premarket on 114% revenue growth and a return …
A bullish Citi Q2 software preview named Figma a top pick and key AI beneficiary alongside Palantir and Microsoft, driving shares sharply higher against a broader technology sector decline. Citi, which maintains a Buy rating with a $36 price target, highlighted Figma's recent acquisition …
Renewed U.S.-Iran hostilities rattled markets, sending oil prices surging and pressuring chip stocks sector-wide, with the Philadelphia Semiconductor Index shedding over 11% since its June record. Compounding near-term sentiment, the company's Chief Strategy Officer Michael Hogan sold 78% of his directly held shares under …
Barclays slashed its price target sharply from $7.00 to $5.00 on July 9 while maintaining an Overweight rating, a notable headwind that shares are edging higher despite. Investor focus is building ahead of the company's Q2 earnings report on August 3, the first to …
Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24. BofA recently raised its price target to $37 while Canaccord sits at $40, but Truist maintained a Hold with a $23 target citing …
Raymond James raised its price target on Delek from $60 to $70 while maintaining an Outperform rating, a significant analyst catalyst for the stock. U.S.-Iran tensions are pushing crude oil prices sharply higher, with energy emerging as a leading sector for Q2 earnings growth.
The decline follows completion of the sale of sevasemten and the company's muscular dystrophy business to Servier for $1.55 billion upfront, up to $2.65 billion total, as Edgewise pivots fully to cardiovascular drugs. The pullback appears driven by profit-taking following a roughly 23.5% five-day …
A broader pullback in basic materials weighs on shares, with the XLB sector ETF also trading lower and the materials sector posting its worst weekly performance last week, down 2.46%. Trump's renewed Greenland ambitions at the NATO summit in Ankara last week briefly lifted …
The healthcare sector is under pressure heading into Q2 earnings season, with the XLV ETF trading modestly lower and a reported 9% Q2 earnings decline for the sector, largely driven by accounting quirks at Gilead. Despite near-term headwinds, analyst sentiment on Definium remains constructive: …
Please wait processing your request...